[Fundamental and clinical studies of cefuroxime in pediatric purulent meningitis (author's transl)].
The following results were obtained from the fundamental and clinical studies of cefuroxime, a new synthetic cephalosporin, in pediatric patients with purulent meningitis. This drug was administered to 2 pediatric patients with purulent meningitis at the dose to 50 mg/kg, by intravenous drip infusion over 30 minutes and one shot intravenous injection respectively. When spinal fluid levels were determined, about 15 approximately 30% of the drug concentration in blood was found to transfer to spinal fluid at acute stage. Spinal fluid levels were about 4 approximately 7 micrograms/ml. When 4 pediatric patients with purulent meningitis were treated with the drug, the good results were obtained in all of them. The dose given was 200 approximately 300 mg/kg/day and the dosing duration was 14 approximately 22 days. No adverse reaction was noted, nor abnormal laboratory test values were noted.
D002444:Cefuroxime / Q000008:administration & dosage* / Q000009:adverse effects / Q000134:cerebrospinal fluid; D002511:Cephalosporins / Q000008:administration & dosage*; D002675:Child, Preschool; D004341:Drug Evaluation; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008581:Meningitis / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D008583:Meningitis, Haemophilus / Q000188:drug therapy
D002511:Cephalosporins; D002444:Cefuroxime